Open AccessResearch Progress of Epithelial-mesenchymal Transition Treatment and Drug Resistance in Colorectal Cancer
Author(s) -
Qianyang Ni,
Meng Li,
Suyang Yu
Publication year - 2022
Publication title -
technology in cancer research and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.754
H-Index - 63
eISSN - 1533-0346
pISSN - 1533-0338
DOI - 10.1177/15330338221081219
Subject(s) - epithelial–mesenchymal transition , colorectal cancer , metastasis , drug resistance , medicine , cancer research , infiltration (hvac) , mesenchymal stem cell , cancer , oncology , pathology , biology , physics , microbiology and biotechnology , thermodynamics
Colorectal cancer (CRC) is one of the most common malignancies in the world that seriously affects human health. Activation of epithelial-mesenchymal transition (EMT) is a physiological phenomenon during embryonic development that is essential for cell metastasis. EMT participates in various biological processes associated with trauma repair, organ fibrosis, migration, metastasis, and infiltration of tumor cells. EMT is a new therapeutic target for CRC; however, some patients with CRC develop resistance to some drugs due to EMT. This review focuses specifically on the status of treatments that target the EMT process and its role in the therapeutic resistance observed in patients with CRC.